The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000585325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
11/02/2026
Date registered
Help: Date registered
11/05/2026
Date last updated
Help: Date last updated
3/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
11/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
PaedNeoVax - A phase I clinical trial to assess safety and efficacy of personalised mRNA vaccine for children and young adults with high-risk brain tumours
Scientific title
Multicentre, investigator-initiated phase I clinical trial to assess safety and efficacy of personalised mRNA vaccine targeting tumour-associated neoantigens in children and young adults with high-risk brain tumours: the PaedNeoVax study
Additional trial identifiers [1] 316476 0
None
Universal Trial Number (UTN)
Trial acronym
PaedNeoVax
Related trial records

Health condition
Health condition(s) studied:
Brain Cancer 340593 0
Condition category
Condition code
Cancer 336792 336792 0 0
Brain
Cancer 336793 336793 0 0
Children's - Brain

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
PTX-108 is a personalised mRNA anti-tumour vaccine designed for the treatment of young patients with brain cancer. The vaccine comprises an individualised mRNA sequence encapsulated in a common lipid nanoparticle. This phase I clinical trial will investigate the safety and efficacy of the personalised PTX-108 mRNA cancer vaccine in paediatric and young adult patients with high-risk brain tumours including relapsed or refractory high-grade tumours and patients with newly diagnosed Diffuse Midline Glioma (DMG) following completion of radiation therapy.

Phase I of the trial will evaluate safety of the personalised vaccine and establish the recommended phase II dose (RP2D).

The vaccine will be given into the muscle, either in the upper arm or the thigh, depending on what is most suitable for the participant. The dose of vaccine administered is determined based on whether the participant experiences any dose limiting toxicities (DLT) (doses 1 to 4) or dose modifying toxicities (DMT) (subsequent doses) following their most recent vaccine dose,

Participant one will be treated with four escalating doses from 50 micrograms to a maximum of 200 micrograms (irrespective of size) and then four further doses at their maximum tolerated dose plus a booster dose at six months from treatment commencement. If the planned maximum dose of 200 microgram is tolerated, the next three participants will receive 9 doses at 200microgram, without escalation.

If no concerns are identified, the study will proceed to phase II after the first four participants have completed the first four vaccine doses. Phase II is described in a separate entry within this registry. If toxicity concerns are identified, the phase I study will revert to a 3+3 design to identify the Recommended Phase 2 Dose (RP2D). This 3+3 design would start at 50 micrograms. Cohorts of three participants will be enrolled at escalating dose levels (50, 100, 200 micrograms), with expansion to six participants if one dose-limiting toxicity (DLT) occurs; dose escalation will proceed if no more than one of the six participants experience a DLT, and the recommended Phase II dose (RP2D) will be defined as the highest dose at which no more than one of six participants experiences a DLT.

The total duration of therapy will be around 26 weeks. Adherence is assessed through directly observed administration of the vaccine by qualified staff during scheduled in-clinic visits, with detailed documentation of attendance and dose administration in study records.

The below describes the schedule for the first participant in this phase of the study. Participants 2 - 4 dosing will be determined based on participant 1 results:

Dose 1:
Administered on Day 1
Dose - 50 micrograms

Dose 2:
Administered on Day 10
Dose if no DLT/DMT - 100 micrograms
Dose following previous DLT/DMT - 50 micrograms

Dose 3:
Administered on Day 24
Dose if no DLT/DMT - 200* micrograms
Dose following previous DLT/DMT - 100 micrograms

Dose 4:
Administered on Day 38
Dose if no DLT/DMT - 200* micrograms
Dose following previous DLT/DMT - 100 micrograms

Dose 5:
Administered on Day 52
Dose if no DLT/DMT - 200* micrograms
Dose following previous DLT/DMT - 100 micrograms

Dose 6:
Administered on Day 66
Dose if no DLT/DMT - 200* micrograms
Dose following previous DLT/DMT - 100 micrograms

Dose 7:
Administered on Day 80
Dose if no DLT/DMT - 200* micrograms
Dose following previous DLT/DMT - 100 micrograms

Dose 8:
Administered on Day 94
Dose if no DLT/DMT - 200* micrograms
Dose following previous DLT/DMT - 100 micrograms

Dose 9 (Booster):
Administered on Day 180 - 190
Dose if no DLT/DMT - 200* micrograms
Dose following previous DLT/DMT - 100 micrograms

*200 micrograms or best tolerated dose level; From 2nd dose, +/- 2 days to accommodate for participant or clinic availability.
Intervention code [1] 333141 0
Treatment: Drugs
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344316 0
Evaluate the safety and tolerability of the personalised mRNA vaccine, This will be assessed as a composite outcome.
Timepoint [1] 344316 0
From first dose through 28 days post last dose
Primary outcome [2] 344317 0
To determine the maximum tolerated and effective dose (MTED) and Recommended Phase 2 Dose (RP2D) of the personalised mRNA vaccine
Timepoint [2] 344317 0
After completion of Phase I dosing, see statistical methods for more information.
Secondary outcome [1] 457492 0
Tumour-derived neoantigens and tumour-associated antigens (TAAs) assessed as a composite outcome
Timepoint [1] 457492 0
Study Completion, at 24 months after study enrolment

Eligibility
Key inclusion criteria
Each participant must meet all the following criteria to be enrolled in this trial:

Age: Participant must be between 6 months and 25 years at the time of enrolment.


Histological confirmation of one of the following high risk central nervous system tumours (either at initial diagnosis or relapsed/refractory disease):
- Any relapsed/refractory WHO grade 3 or 4 central nervous system tumour
- Newly diagnosed diffuse midline glioma in a patient anticipated to be able to start study therapy within 20 weeks post biopsy
- Newly diagnosed high risk medulloblastoma, ependymoma, or other high-risk brain tumour after discussion with the study chairs (includes p53-mutant SHH medulloblastoma, PFA ependymoma with 6q deletion and/or 1q gain or other high risk molecular alterations associated with less than 20% anticipated 5 year survival) who are anticipated to be able to proceed to PTX-108 therapy after completion of institutional standard-of-care treatment.


Co-enrolment on the Zero Childhood Cancer (ZERO) molecular profiling platform (repeat tumour sampling in relapsed patients to obtain a current representative sample), with successful tumour WGS +/- RNA-seq analysis with a requirement of at least five potential neoantigens or tumour-associated antigens (TAAs) for vaccine production.


Informed consent as demonstrated by a signed and dated informed consent form completed by the participant or a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant’s behalf.



For a participant to commence personalised PTX-108 vaccine therapy (Reassessment), participants must be re-screened within 7 days of anticipated treatment start date (28 days for imaging) and the following criteria must be met:

- Confirmation of individualised PTX-108 vaccine available at the treating site for the participant.

- Measurable disease as per RAPNO/RANO 2.0 criteria (any previously irradiated lesion needs to have progressed since prior radiation therapy except for participants with newly diagnosed DMG and other high-risk brain tumours proceeding to vaccine therapy after completion of standard frontline therapy). Newly diagnosed patients eligible for study otherwise without measurable disease can be enrolled on review with the study team.

- Lansky/Karnofsky performance score of greater than 50. Use Karnofsky for patients over 16 years of age and Lansky for patients less than 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

- Life expectancy of at least 12 weeks at the time of re-screening. No clinical or radiological evidence of brain herniation or significant mass effect resulting in risk of imminent neurological deterioration.

- Prior therapy: Patients must have fully recovered from prior anti-cancer therapy including
~Myelosuppressive chemotherapy: Greater than 21 days between prior myelosuppressive therapy and PTX-108 commencement (or more than 42 days since last dose of nitrosourea).
~Non-myelosuppressive anticancer agents: greater than 7 days after the last dose.
~Immunotherapy: greater than 42 days after the last dose
~Monoclonal antibodies: greater than 21 days after the last dose.
~Radiation therapy: greater than 4 weeks after completion of radiation including CSI but within 12 weeks of biopsy for those patients with newly diagnosed DMG.

- Haematopoietic growth factor: greater than 14 days for long acting (peg-filgrastim) or greater than 7 days for short acting growth factor.

- Adequate haematologic function defined as:
~Haemoglobin greater than or equal to 80 g/L (post transfusion permitted)
~Absolute Neutrophil Count (ANC) greater than or equal to 1.0 x109/L
~Absolute Lymphocyte Count greater than or equal to 1.0 x109/L
~Platelet count greater than or equal to 75 x109/L (cannot be post-transfusion)

- Adequate renal function defined as:
~Serum creatinine = Less than 1.5x institutional upper limit of normal (ULN) for age and sex

- Adequate liver function defined as:
~Total bilirubin = Less than 1.5 x upper limit of normal (ULN) for age
~AST and ALT = Less than 5 x upper limit of normal (ULN) for age
~Adequate coagulation (INR, PT and aPTT = Less than 1.5 times ULN)

Investigator confirmation that the participant has no other serious medical conditions which are considered by the investigator to unacceptably increase the risk to the participant
Minimum age
6 Months
Maximum age
25 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Exclusion Criteria for Study Enrolment:

Known hypersensitivity to mRNA vaccines

Administration of live vaccines within 3 months of starting protocol therapy

Pregnant and breastfeeding females

Underlying congenital immunodeficiency



Exclusion Criteria for Vaccine Therapy:

Administration of live vaccine within 4 weeks of planned vaccine therapy commencement

Pregnant and breastfeeding females

No current corticosteroid therapy other than physiologic replacement doses equivalent to hydrocortisone maximum 20mg/m2/day

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
If no Dose Limiting Toxicity (DLT) is seen in the first participant when escalated to 3rd dose (200 micrograms), 3 further participants will be enrolled at this dose level to confirm safety. If DLTs are found at any dose levels, the DSMC and study team will assess dosing at lower levels utilising a conventional 3+3 design. We predict no more than 10 patients in the Phase I study. This assumes an expected immune response rate of 50% (as per pancreatic cancer studies) where the probability of observing at least one response in the first four participants would be: 1 - (0.5^4) = 94% and 99% with 7 patients.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA,VIC

Funding & Sponsors
Funding source category [1] 321087 0
Government body
Name [1] 321087 0
Australian Department of Health and Aged Care, Medical Research Future Fund (MRFF)
Country [1] 321087 0
Australia
Primary sponsor type
Other Collaborative groups
Name
Australian and New Zealand Children's Haematology Oncology Group
Address
Country
Australia
Secondary sponsor category [1] 323793 0
None
Name [1] 323793 0
Address [1] 323793 0
Country [1] 323793 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319619 0
Women's and Children's Health Network Human Research Ethics Committee
Ethics committee address [1] 319619 0
Ethics committee country [1] 319619 0
Australia
Date submitted for ethics approval [1] 319619 0
24/03/2026
Approval date [1] 319619 0
14/05/2026
Ethics approval number [1] 319619 0
2026/HRE00092

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 147890 0
Prof Jordan R. Hansford
Address 147890 0
Women’s and Children’s Hospital, 72 King William Road, North Adelaide SA 5006
Country 147890 0
Australia
Phone 147890 0
+61 8 8161 7000
Fax 147890 0
Email 147890 0
Contact person for public queries
Name 147891 0
Jordan R. Hansford
Address 147891 0
Women’s and Children’s Hospital, 72 King William Road, North Adelaide SA 5006
Country 147891 0
Australia
Phone 147891 0
+61 8 8161 7000
Fax 147891 0
Email 147891 0
Contact person for scientific queries
Name 147892 0
Brandon Wainwright
Address 147892 0
Frazer Institute, University of Queensland, St Lucia QLD 4072
Country 147892 0
Australia
Phone 147892 0
+61 7 3365 1111
Fax 147892 0
Email 147892 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.